Safety, Pharmacokinetics, and Efficacy of Olorinab, a Peripherally Acting, Highly Selective, Full Agonist of the Cannabinoid Receptor 2, in a Phase 2a Study of Patients with Chronic Abdominal Pain Associated with Crohn's Disease
Bruce R. Yacyshyn*, Stephen Hanauer, Preston Klassen, Brett A. English, Kathe Stauber, Charles F. Barish, Kye Gilder, Stewart Turner, Peter D.R. Higgins
Dive into the research topics of 'Safety, Pharmacokinetics, and Efficacy of Olorinab, a Peripherally Acting, Highly Selective, Full Agonist of the Cannabinoid Receptor 2, in a Phase 2a Study of Patients with Chronic Abdominal Pain Associated with Crohn's Disease'. Together they form a unique fingerprint.